Abstract
Summary
Recombinant DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.
The global market for Recombinant DNA Vaccine was estimated to be worth US$ 186 million in 2023 and is forecast to a readjusted size of US$ 502.8 million by 2030 with a CAGR of 15.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant DNA Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant DNA Vaccine by region & country, by Type, and by Application.
The Recombinant DNA Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant DNA Vaccine.
Market Segmentation
By Company
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Segment by Type:
Recombinant Protein Vaccine
Gene-Based Vaccine
Segment by Application
Human
Animal
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant DNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant DNA Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant DNA Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Recombinant DNA Vaccine was estimated to be worth US$ 186 million in 2023 and is forecast to a readjusted size of US$ 502.8 million by 2030 with a CAGR of 15.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant DNA Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant DNA Vaccine by region & country, by Type, and by Application.
The Recombinant DNA Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant DNA Vaccine.
Market Segmentation
By Company
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Segment by Type:
Recombinant Protein Vaccine
Gene-Based Vaccine
Segment by Application
Human
Animal
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant DNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant DNA Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant DNA Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Recombinant DNA Vaccine Product Introduction
1.2 Global Recombinant DNA Vaccine Market Size Forecast
1.2.1 Global Recombinant DNA Vaccine Sales Value (2019-2030)
1.2.2 Global Recombinant DNA Vaccine Sales Volume (2019-2030)
1.2.3 Global Recombinant DNA Vaccine Sales Price (2019-2030)
1.3 Recombinant DNA Vaccine Market Trends & Drivers
1.3.1 Recombinant DNA Vaccine Industry Trends
1.3.2 Recombinant DNA Vaccine Market Drivers & Opportunity
1.3.3 Recombinant DNA Vaccine Market Challenges
1.3.4 Recombinant DNA Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant DNA Vaccine Players Revenue Ranking (2023)
2.2 Global Recombinant DNA Vaccine Revenue by Company (2019-2024)
2.3 Global Recombinant DNA Vaccine Players Sales Volume Ranking (2023)
2.4 Global Recombinant DNA Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Recombinant DNA Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Recombinant DNA Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Recombinant DNA Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Recombinant DNA Vaccine
2.9 Recombinant DNA Vaccine Market Competitive Analysis
2.9.1 Recombinant DNA Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant DNA Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant DNA Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Recombinant Protein Vaccine
3.1.2 Gene-Based Vaccine
3.2 Global Recombinant DNA Vaccine Sales Value by Type
3.2.1 Global Recombinant DNA Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant DNA Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant DNA Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Recombinant DNA Vaccine Sales Volume by Type
3.3.1 Global Recombinant DNA Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Recombinant DNA Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Recombinant DNA Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Recombinant DNA Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Human
4.1.2 Animal
4.2 Global Recombinant DNA Vaccine Sales Value by Application
4.2.1 Global Recombinant DNA Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant DNA Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant DNA Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Recombinant DNA Vaccine Sales Volume by Application
4.3.1 Global Recombinant DNA Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Recombinant DNA Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Recombinant DNA Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Recombinant DNA Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant DNA Vaccine Sales Value by Region
5.1.1 Global Recombinant DNA Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant DNA Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Recombinant DNA Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Recombinant DNA Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Recombinant DNA Vaccine Sales Volume by Region
5.2.1 Global Recombinant DNA Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Recombinant DNA Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Recombinant DNA Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Recombinant DNA Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Recombinant DNA Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Recombinant DNA Vaccine Sales Value, 2019-2030
5.4.2 North America Recombinant DNA Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Recombinant DNA Vaccine Sales Value, 2019-2030
5.5.2 Europe Recombinant DNA Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Recombinant DNA Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Recombinant DNA Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Recombinant DNA Vaccine Sales Value, 2019-2030
5.7.2 South America Recombinant DNA Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Recombinant DNA Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Recombinant DNA Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant DNA Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant DNA Vaccine Sales Value
6.2.1 Key Countries/Regions Recombinant DNA Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Recombinant DNA Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Recombinant DNA Vaccine Sales Value, 2019-2030
6.3.2 United States Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant DNA Vaccine Sales Value, 2019-2030
6.4.2 Europe Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant DNA Vaccine Sales Value, 2019-2030
6.5.2 China Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant DNA Vaccine Sales Value, 2019-2030
6.6.2 Japan Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant DNA Vaccine Sales Value, 2019-2030
6.7.2 South Korea Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant DNA Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant DNA Vaccine Sales Value, 2019-2030
6.9.2 India Recombinant DNA Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant DNA Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Recombinant DNA Vaccine Product Offerings
7.1.5 Merck Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Introduction and Business Overview
7.2.3 GSK Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 GSK Recombinant DNA Vaccine Product Offerings
7.2.5 GSK Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Information
7.3.2 Sanofi Introduction and Business Overview
7.3.3 Sanofi Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Recombinant DNA Vaccine Product Offerings
7.3.5 Sanofi Recent Development
7.4 Zoties
7.4.1 Zoties Company Information
7.4.2 Zoties Introduction and Business Overview
7.4.3 Zoties Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Zoties Recombinant DNA Vaccine Product Offerings
7.4.5 Zoties Recent Development
7.5 Elanco
7.5.1 Elanco Company Information
7.5.2 Elanco Introduction and Business Overview
7.5.3 Elanco Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Elanco Recombinant DNA Vaccine Product Offerings
7.5.5 Elanco Recent Development
7.6 Boehringer-Ingelheim
7.6.1 Boehringer-Ingelheim Company Information
7.6.2 Boehringer-Ingelheim Introduction and Business Overview
7.6.3 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Boehringer-Ingelheim Recombinant DNA Vaccine Product Offerings
7.6.5 Boehringer-Ingelheim Recent Development
7.7 Indian Immunologicals
7.7.1 Indian Immunologicals Company Information
7.7.2 Indian Immunologicals Introduction and Business Overview
7.7.3 Indian Immunologicals Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Indian Immunologicals Recombinant DNA Vaccine Product Offerings
7.7.5 Indian Immunologicals Recent Development
7.8 Plumbline Life Sciences
7.8.1 Plumbline Life Sciences Company Information
7.8.2 Plumbline Life Sciences Introduction and Business Overview
7.8.3 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Plumbline Life Sciences Recombinant DNA Vaccine Product Offerings
7.8.5 Plumbline Life Sciences Recent Development
8 Industry Chain Analysis
8.1 Recombinant DNA Vaccine Industrial Chain
8.2 Recombinant DNA Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant DNA Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant DNA Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer